Charles River Laboratories International, Inc.

CRL Healthcare Diagnostics & Research

Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

299.77 6.47 −2.11%
Market cap
$14.6B
P/E
0.0×
Fwd P/E
29.6×
Dividend yield
—
F-score
5/9
Altman Z
2.40
Beneish M
−3.11
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(7.69%) (6.01%) (4.35%) (2.48%)

+8 more TTM periods

Piotroski F-Score
5 4 5 4
ROA
(3.16%) (2.41%) (1.97%) (1.15%)
ROIC
1.07% 0.81% 0.31% 1.63%
Return on Tangible Assets
(12.62%) (9.69%) (7.28%) (4.45%)
Average Days of Receivables
64.96 63.47 64.44 66.63
Free Cash Flow per Share
7.72 7.99 10.46 11.05
Free Cash Flow
370.61 391.29 518.49 543.67
Other line items

Show all line items

Columns are period end dates